Roche relaunches refillable wet AMD implant two years after recall
The Susvimo eye implant is filled with customised formulation of Lucentis, which delivers the therapy continuously and eliminates the need for multiple injections.
10 July 2024
10 July 2024
The Susvimo eye implant is filled with customised formulation of Lucentis, which delivers the therapy continuously and eliminates the need for multiple injections.
Its lead candidate, SR-878, is a monoclonal antibody targeting iRhom2, with a clinical trial commending in the second half of 2024.
Evotec plans to undertake research activities at its facilities in France, including the advanced Campus Curie research site.
iTeos will receive $35m from GSK as the first patient is dosed in the Phase III trial of the jointly developed monoclonal antibody EOS-448.
The once-daily oral capsule prevents HAE attacks by inhibiting plasma kallikrein activity.
iOnctura will evaluate roginolisib in combination with GSK’s Jemperli in a Phase II trial.
The merged entity comprises a comprehensive team of experts in government pricing and payer/provider contracting.
Taiho will make an option exercise payment for obtaining exclusive rights to quemliclustat.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.